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Summary The purpose of this retrospective study was to determine the effects of
long-term treatment with montelukast on chronic obstructive pulmonary disease
(COPD) control in a cohort of patients with moderate to severe COPD. The medical
records of 20 consecutive male patients (18 African-Americans) aged 71.2710.7 years
diagnosed with moderate to severe COPD at the VA Chicago Health Care System,
Chicago, Illinois, USA, and treated with oral montelukast, 10mg every night, for
23.677.3 months were reviewed. Information on demographics and COPD control was
extracted from each record. In each patient, a comparable follow-up period in the
clinic before and after initiating montelukast therapy was reviewed and tabulated so
each patient served as his own control. There was a significant improvement in
complaints of shortness of breath, sputum production wheezing and nocturnal
symptoms during the observation period (Po0:05). There was a significant reduction
in the use of oral and inhaled corticosteroids, inhaled bronchodilators and
supplemental oxygen (Po0:05). In addition, there was a significant reduction in the
number of visits to the emergency department, number of hospitalizations and
duration of hospitalizations for acute exacerbations of COPD (Po0:05). No significant
changes in FEV1 (% predicted), FEV1/FVC ratio (% predicted) and peak expiratory flow
rate were recorded during this time. No side effects where reported during the
observation period and no patient discontinued the medication. Collectively, these
data suggest that long-term treatment with montelukast is safe and improves COPD
control in elderly patients with moderate to severe COPD.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Despite recent advances in medical therapeutics,
treatment of patients with chronic obstructive
pulmonary disease (COPD) remains largely sympto-
matic and, as such, represents an unmet medical
need.1 This notion has important medical and
socio-economic implications given that COPD is a
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leading cause of chronic morbidity and mortality in
the USA, and is predicted to rank fifth in worldwide
burden of disease by the year 2020.2,3 Hence, there
is an urgent need to develop and test new drugs
that target pathophysiological mechanisms under-
lying COPD.4
To this end, cysteinyl leukotrienes (leukotriene
C4, D4 and E4) are potent pro-inflammatory media-
tors implicated in the pathogenesis of certain
inflammatory lung diseases, including asthma.5,6
They have been shown to increase microvascular
permeability, evoke mucus hypersecretion and
elicit potent airway smooth muscle contraction.6
Some of these features are also present in the
airway mucosa of patients with COPD.1 It is
well established that the concentrations of
cysteinyl leukotrienes are increased in the sputum,
plasma and circulating leukocytes of patients
with COPD implying that they could play a role
in the pathophysiology of this disorder.7–13 How-
ever, unlike certain patients with asthma, the
effects of long-term therapy with cysteinyl leuko-
triene receptor antagonits on COPD control are
uncertain.14–19
Hence, the purpose of this retrospective study
was to begin to address this issue by determining
the effects of long-term treatment with montelu-
kast, a cysteinyl leukotriene receptor antago-
nist,6,18,20 on COPD control in a cohort of elderly
patients with moderate to severe COPD residing in
inner-city Chicago.
Methods
Patients
The medical records of all patients with the
diagnosis of moderate to severe COPD by estab-
lished ATS criteria21 followed at the Chest Clinic of
the VA Chicago Health Care System in Chicago and
treated with oral montelukast, 10mg every night,
for at least 12 months were reviewed. All patients
were ex-smokers (pack year, 4372) and had
irreversible airflow obstruction (increase in FEV1
of o10% or o200ml after inhaling a bronchodila-
tor) on spirometry. They were non-smokers because
every smoking patient attending the Chest Clinic is
encouraged to quit smoking by clinic’s personnel.
None reported a history of asthma or other
respiratory disorders. Montelukast was prescribed
at the discretion of the physician in the Chest Clinic
when the patient’s respiratory complaints were no
longer amenable to conventional therapy or shortly
after recovering from an acute exacerbation of
COPD.
Information about age, race, duration of COPD,
self-reported symptoms of COPD, use of anti-COPD
medications, duration of montelukast therapy, FEV1
(% predicted), FEV1/FVC ratio (% predicted), peak
expiratory flow rate, number of visits to the
emergency department for acute exacerbations of
COPD, number of hospitalizations for an acute
exacerbation of COPD, duration of hospitalization
for an acute exacerbation of COPD and duration of
follow-up at the outpatient clinic was retrieved
from each record. In each patient, a comparable
follow-up period in the clinic before and after
initiating montelukast therapy was reviewed and
tabulated so each patient served as his/her own
control. The need for supplemental oxygen was
gauged in each patient during clinic visits at rest
and after walking in the clinic while breathing
ambient air. Supplemental oxygen was discontinued
or prescribed if transcutaneous oxyhemoglobin
saturation was 90% and above or 88% and below,
respectively.
A retrospective comparison of outcome measures
between patients with moderate to severe COPD
treated with montelukast to those who were not
treated over the observation period was beyond the
scope of this study. In addition, only spirometry was
available for each patient to review so other
parameters of pulmonary function, including arter-
ial blood gases, are not reported. The study was
approved by the Institutional Review Board.
Data and statistical analyses
Data are expressed as means7SD. Data were
analyzed by Fisher’s exact test and Mann–Whitney
U-test as indicated. Normality of distribution was
analyzed with the Smirnov–Kolmogorov test and log
transformation was used to normalize data dis-
tribution. A Po0:05 was considered statistically
significant.
Results
Twenty male patients with moderate to severe
COPD aged 71.2710.7 years were enrolled in this
study. Eighteen were African-Americans, one Cau-
casian and one Hispanic. All used inhaled bronch-
odilators daily, 12 patients were treated with
prednisone on a regular basis, 15 used Inhaled
corticosteroids daily some of which in combination
with prednisone, and seven were using supplemen-
tal oxygen 24 h/day.
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All 20 patients were treated with montelukast for
23.677.3 months (range, 12–38 months). No
adverse events to montelukast were recorded and
no patient discontinued the drug during the
observation period of this study. The characteristics
of the patients before and after initiation of
montelukast therapy are outlined in Table 1.
Long-term montelukast therapy was associated
with significant improvement in self-reported
shortness of breath, copious sputum production,
wheezing and nocturnal symptoms (Table 1;
Po0:05). The decrease in self-reported shortness
of breath from 95% before to 38% after initiation of
montelukast therapy, and in copious sputum pro-
duction from 80% before to 25% after initiation of
montelukast therapy were particularly noteworthy.
These salutary effects were associated with a
significant reduction in regular use of prednisone,
inhaled corticosteroids, inhaled bronchodilators
and supplemental oxygen (Table 1; Po0:05). The
reduction in regular use of prednisone and inhaled
corticosteroids was from 60% to 25% and from 75%
to 44%, respectively (Table 1; Po0:05).
Importantly, there was a significant reduction in
the number of visits to the emergency department
for acute exacerbations of COPD, number of
hospitalizations for acute exacerbations of COPD
and duration of hospitalization for acute exacerba-
tions of COPD (Table 1; Po0:05). There was no
significant change in FEV1 (% predicted), FEV1/FVC
ratio (% predicted) and peak expiratory flow rate
during the observation period (Table 1; P40:5).
Discussion
The new finding of this study is that treatment with
montelukast, 10mg every night, for 12–38 con-
secutive months is associated with significant
improvement in COPD control in elderly, predomi-
nantly African-American, patients with moderate
to severe COPD residing in inner-city Chicago. The
salutary effects of montelukast were noted in
clinical, medication use, particularly prednisone
and inhaled corticosteroids, and hospital visits and
admissions for acute exacerbations of COPD over
the observation period. By contrast, montelukast
had no significant effects on FEV1, FEV1/FVC and
peak expiratory flow rates, which are measures
of central airway function, suggesting that it does
not target the central airways of patients with
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Table 1 Characteristics of patients with moderate to severe COPD on long-term montelukast therapy.
Characteristic Montelukast
Before After
Number of patients 20 20
Age (yr) 71.2710.7 F
Duration of COPD (yr) 9.976.4 F
Duration of montelukast therapy (mo) F 23.677.3
Self-reported shortness of breath (%) 95 38*
Copious sputum production (%) 80 25*
Self-reported wheezing (%) 65 31*
Self-reported nocturnal symptoms (%) 25 6*
FEV1 (%predicted) 42718 40720
FEV1/FVC (% predicted) 57711 57717
PEFR (l/min) 218790 218786
Regular use of prednisone (%) 60 25*
Regular use of inhaled bronchodilators (%) 100 81*
Regular use of Inhaled corticosteroids (%) 75 44*
Need for supplemental oxygen (%) 35 25*
No. of ED visits for AE of COPD (yr) 3.372.8 1.271.9*
No. of hospitalizations for AE of COPD (yr) 2.672.3 0.971.7*
Duration of hospitalization (days) 5.375.5 1.775.0*
Data are means7SD; *Po0:05 in comparison to before montelukast therapy; yr, year; mo, month; ED, emergency department;
and AE, acute exacerbation.
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moderate to severe COPD in which fixed airway
obstruction predominates.1,14–16 Taken together,
these data suggest that long-term (at least 12
months) montelukast therapy is associated with
significant improvement in COPD control in elderly
patients with moderate to severe COPD.
It is well established that airway inflammation
characterized, in part, by increased microvascular
permeability, mucus hypersecretion, neutrophil
infiltration and tissue remodeling is present
in patients with moderate to severe COPD.1,22
However, current therapeutic modalities recom-
mended to circumvent this harmful and relentless
process, including corticosteroids, do not target
certain key components of the inflammatory
cascade in the airway mucosa of patients with
COPD, such as increased microvascular permeabil-
ity and mucus hypersecretion.1,4,19,22 Moreover,
unlike montelukast, they are froth with potentially
serious adverse events, particularly among elderly
individuals.4 Hence, there is an urgent need to
develop and test new drugs that interrupt specific
inflammatory pathways thought to play an impor-
tant role in the pathophysiology of moderate to
severe COPD.
The concentration of cysteinyl leukotrienes is
increased in the sputum, plasma and circulating
leukocytes of patients with COPD.7–13 To this end,
Shindo et al.13 showed that circulating LTE4 con-
centration increases significantly during acute
exacerbations of COPD. Conceivably, elaboration
of cysteinyl leukotrienes could play a role in
the pathophysiology of airway inflammation in
these patients. These data coupled with the
results of the present study suggest that long-term
administration of cysteinyl leukotriene receptor
antagonists, such as montelukast, could be bene-
ficial in patients with moderate to severe COPD.
Alternatively, montelukast may express anti-in-
flammatory properties that are unrelated to its
cysteinyl leukotriene receptor antagonism in pa-
tients with moderate to severe COPD. Additional
studies are indicated to support or refute these
hypotheses.
Cazzola et al.14,15 showed that zafirlukast, a
cysteinyl leukotriene receptor antagonist, given for
2 or 4 non-consecutive days elicited a significant
increase in FEV1 in a small number of patients with
stable moderate to severe COPD. The results of this
study show that long-term (months) treatment with
montelukast, 10mg every night, is associated with
significant improvement in COPD control with no
appreciable change in FEV1 in elderly predomi-
nantly African-American patients with moderate to
severe COPD. The discrepant results between both
studies are difficult to reconcile but may be
related, in part, to differences in race, duration
of treatment and perhaps inclusion of patients with
COPD and a previously unrecognized history of
asthma in the former.
The cellular origin of cysteinyl leukotrienes in
the airway, the role of pro-inflammatory mediators
elaborated by neutrophils and other cells through
the 5-lipoxygenase activating protein (FLAP)/5-
lipoxygenase metabolic pathway of arachidonic
acid metabolism, such as leukotriene B4, were
not elucidated in this study.23 To this end, Lee
et al.22 showed that inhibitors of 5-lipoxygenase
reverse neutrophil survival promoted by several
pro-inflammatory mediators in patients with COPD
in vitro. However, Gompertz and Stockley16 showed
recently that 14-day therapy with a selective
inhibitor of FLAP had only modest effects of certain
parameters of inflammation in the sputum of
patients with severe COPD. No other outcome
measures were reported by these authors. Clearly,
further studies using molecular, biochemical and
cell biology techniques are warranted to address
these issues.
The limitations of the present study are obvious.
It is retrospective and encompasses only a
relatively small number of predominantly African-
American patients with moderate to severe COPD
who were all ex-smokers. Hence, the applicability
of the results of this study to a larger group
of patients, and to patients with moderate to
severe COPD who still smoke is uncertain. In
addition, the improvement in COPD control was
predominantly subjective, and the observed reduc-
tion in corticosteroids use during montelukast
therapy might have been attributed to their lack
of effectiveness in these patients. Nonetheless, the
marked reductions in the number of visits to the
emergency department for acute exacerbations of
COPD, the number of hospitalizations for acute
exacerbations of COPD and the duration of hospi-
talization for acute exacerbations of COPD are
noteworthy. On aggregate, these data suggest that
the salutary effects of long-term montelukast
therapy in elderly patients with moderate to severe
COPD could have been attributed, in part, to the
drug. We propose that larger, multi-center, double-
blind, randomized, placebo-controlled clinical
trials should be contemplated to determine the
efficacy of long-term montelukast therapy in
smoking and ex-smoking patients with moderate
to severe COPD.
In summary, we found that long-term (at least 12
months) montelukast therapy, 10mg every night, is
safe and associated with significant improvement in
COPD control in elderly patients with moderate to
severe COPD.
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